Igyxos S.A.
Have updates for this profile? Please contribute data
= Subscriber Access Only
You are viewing a preview of this profile. Request a Preqin Pro demo for full access to all profiles and underlying data.
With Preqin Pro, you gain an unobstructed view of all alternative asset class activity across institutional investors, fund managers, funds, portfolio companies, deals, exits, and service providers.
Igyxos S.A. - overview
Established
2017
Location
-, -, France
Primary Industry
Pharmaceuticals
About
Igyxos S. A. is a biotherapeutics company focused on developing innovative treatment solutions for infertility using monoclonal antibodies, particularly targeting the efficacy of Follicle Stimulating Hormone (FSH). Founded in 2017 in France, Igyxos S.
A. specializes in infertility therapeutics, including its lead clinical candidate IGX12. The company has completed 4 funding deals, with the most recent being a Series A round in February 2024, raising EUR 4. 40 mn from investors such as Bpifrance Investissement, GO CAPITAL, and Sofimac Partners.
The current company valuation stands at EUR 13. 196 mn. The founder, Marie-Christine Maurel, is known for her contributions in the biotherapeutics sector, although specific prior ventures are not detailed. Igyxos Biotherapeutics specializes in developing innovative therapeutic solutions for infertility, focusing on monoclonal antibodies, with its flagship candidate IGX12 aimed at enhancing the effectiveness of Follicle Stimulating Hormone (FSH).
The company primarily serves healthcare providers, fertility clinics, and reproductive health specialists across Europe, North America, and Asia, addressing the needs of approximately 48 million couples facing infertility. Igyxos Biotherapeutics reported zero revenue for the most recent year, 2018, with an EBITDA loss of EUR 550,957. 8. The company's revenue model involves partnering with healthcare institutions and fertility clinics for its infertility therapies, likely structured around licensing agreements and partnerships that allow for the commercialization of their products.
In February 2024, Igyxos S. A. secured Series A funding of EUR 4. 40 mn to support its growth strategies.
The company aims to launch new infertility treatments, including additional monoclonal antibodies, while expanding its market presence in Europe, North America, and Asia. The recent funding will be instrumental in accelerating product development and enhancing partnerships with healthcare providers to optimize their offerings in reproductive health.
Current Investors
Sofimac Partners, Go Capital, Bpifrance Investissement
Primary Industry
Pharmaceuticals
Sub Industries
Molecular Science, Genetics & Gene Therapy, Pharmaceutical Research & Development
Website
www.igyxos.com
Company Stage
Series A
Total Amount Raised
Subscriber access only
Igyxos S.A. - financials
| Fiscal Year Ended | Dec 31, 2018 |
|---|---|
| Revenue (USD) | - |
| % Revenue Growth (YoY) | - |
| EBITDA (USD) | - |
| Operating Income (USD) | - |
| Operating Margin | - |
| % EBITDA Margin | - |
| NET Income (USD) | - |
| % Net Margin | - |
Igyxos S.A. - employee data
Time to go Pro
Get Preqin Pro for unrestricted access to 600,000+ detailed profiles on fund managers, investors, funds, companies, and other alternative asset players. Unlock exclusive data on future plans, company financials, fundraising history, track records, and more.